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Ob/ob mice provide an animal model for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
(NAFLD/NASH) in patients with obesity and type-2 diabetes. Low liver copper has been linked to hepatic
lipid build-up (steatosis) in animals with systemic copper deﬁciency caused by low-copper diets.
However, hepatic copper status in patients with NAFLD or NASH is uncertain, and a validated animal
model useful for the study of hepatic copper regulation in common forms of metabolic liver disease is
lacking. Here, we report parallel measurements of essential metal levels in whole-liver tissue and
defatted-dried liver tissue from ob/ob and non-obese control mice. Measurements in whole-liver tissue
from ob/ob mice at an age when they have developed NAFLD/NASH, provide compelling evidence for
factitious lowering of copper and all other essential metals by steatosis, and so cannot be used to study
hepatic metal regulation in this model. By marked contrast, metal measurements in defatted-dried liver
samples reveal that most essential metals were actually normal and indicate speciﬁc lowering of copper
in ob/ob mice, consistent with hepatic copper deﬁciency. Thus ob/ob mice can provide a model useful for
the study of copper regulation in NAFLD and NASH, provided levels are measured in defatted-dried liver
tissue.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Mice homozygous for the spontaneous mutation obese (Lepob,
ob/ob), which leads to absolute deﬁciency of the adipocyte-derived
hormone leptin, exhibit hyperphagia and obesity accompanied by a
type-2 diabetes-like syndrome comprising glucose intolerance and
hyperglycaemia [1,2]. In thesemice, the abnormalmetabolic state isiscovery and Experimental
itals NHS Foundation Trust
Unwin), g.cooper@auckland.
r Inc. This is an open access articleaccompanied by several endocrine defects, including elevated
levels of the pancreatic beta-cell hormones insulin and amylin [3],
insulin resistance, and deﬁciency of the second major adipocyte-
derived hormone, adiponectin [2,4]. Obesity in ob/ob mice is
accompanied by an increase in both the number and size of adi-
pocytes; however, although hyperphagia contributes to this
obesity, homozygous animals gain excess weight and deposit
excess fat when restricted to a diet sufﬁcient for normal weight
maintenance in matched non-affected controls [1].
Non-alcoholic fatty liver disease (NAFLD) is a common form of
fatty liver disease that is not caused by excess alcohol intake and is
associated with obesity and insulin resistance. NAFLD can progress
to Non-alcoholic steatohepatitis (NASH), where the steatosis is
associated with inﬂammation and ﬁbrosis, and this in turn canunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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steatosis that worsens with age, from a syndrome resembling
NAFLD in humans to one mirroring NASH [4]. Adiponectin deﬁ-
ciency makes a substantive contribution to the development of
NAFLD and NASH in ob/obmice, and hepatic structure and function
are largely restored by adiponectin treatment [4]. However, adi-
ponectin replacement is not a therapeutic option at present, owing
to the great structural complexity of the hormone and the resulting
inability to produce pure hormone for therapeutic application
[5e7].
Over the last decade, our group has identiﬁed and characterised
a pathogenic disorder of copper regulation, which occurs in dia-
betic patients [8,9] and animals [10e13], and which causes sys-
temic copper overload accompanied by copper imbalance: this
manifests as copper overload in the kidneys [14] but localized
copper deﬁciency in other organs, for example as left-ventricular
copper deﬁciency in diabetic cardiomyopathy [13]. Reversal of
this systemic copper imbalance in patients or animals can be
accomplished by treatment with the Cu(II)-selective chelator,
triethylenetetramine (TETA), which restores systemic copper bal-
ance [8] and normalizes organ copper content and function, for
example in the myocardium [9,13] and kidneys [14]. Hepatic stea-
tosis also occurs in animals with low dietary copper intakes [15] but
the hepatic copper status in patients with NAFLD or NASH remains
to be accurately determined. Importantly, patients and animals
with NAFLD or NASH do not develop typical signs of systemic
copper deﬁciency, which include low plasma copper, low urinary
copper output, low concentration and activity of plasma caer-
uloplasmin, anaemia, neutropenia, and low erythrocyte superoxide
dismutase activity [16].
A recent report has described lowered hepatic copper concen-
trations in patients with NAFLD and NASH [17]. The authors inter-
preted their data to show that lower hepatic copper levels in
patients were associated with more pronounced hepatic steatosis,
NASH, and components of the metabolic syndrome [17]. Further-
more, they also reported development of hepatic steatosis and in-
sulin resistance in response to dietary copper restriction in rats,
which was interpreted to suggest that impaired copper availability
may be involved in the development of NAFLD. Accordingly, they
hypothesized that low hepatic copper might contribute to the
disorder of hepatic lipid metabolism in clinical NAFLD and NASH.
However, organ inﬁltration with elevated concentrations of lipid
causes an excluded-volume effect, for example with respect to
metals ions, that leads to spuriously lowmeasured values for tissue
metals because they are excluded from the expanded lipid
compartment in which they are insoluble; this process is exem-
pliﬁed by factitious hyponatraemia caused by hyper-
triglyceridaemia [18]. In these abovementioned studies of copper in
NAFLD/NASH, hepatic copper levels were determined in non-
defatted, dried hepatic tissue, as is done for the diagnosis of Wil-
son's disease [17,19]. Drying alone does not, however, remove
neutral lipid from tissues. Furthermore, Wilson's disease leads to
marked hepatic copper overloadwith hepatitis, but does not lead to
signiﬁcant steatosis [19], and must therefore be differentiated from
NASH, which does [4]. A method suitable for the measurement of
elevated copper levels in Wilson's disease is thus unlikely to be
applicable for the accurate measurement of deﬁcient copper levels
in NAFLD/NASH, where steatosis is a probable cause for spurious
lowering of metal levels.
It is uncertainwhether elevated hepatic lipid levels are sufﬁcient
to cause factitious lowering of metal levels in ob/ob mice, or
whether these mice develop hepatic copper deﬁciency. Therefore,
we measured metal levels in untreated liver tissue from ob/ob and
control mice, and compared them with levels from the corre-
sponding tissue samples after they had ﬁrst been dried anddefatted. Reported measurements of hepatic copper in patients
with NAFLD or NASH have to date been performed only on dried
hepatic tissue that had not been defatted [17], so it remains to be
determined whether the reported low hepatic copper levels reﬂect
the actual hepatic copper status in such patients, or rather whether
any apparent lowering of hepatic copper is merely factitious.
As a necessary pre-translational stage in the process of proving
that low copper levels might cause damage to a particular organ, it
is necessary to develop an informative animal model. Here, we
describe studies in which we have measured hepatic copper levels
in the livers of ob/ob mice at 11 weeks of age, when they have
developed marked NAFLD/NASH as shown by numerous histolog-
ical and biochemical indices of disease, as we have previously
shown [2,4].We quantitatedmetals inwhole hepatic tissue (mol/kg
wet-weight) and in defatted-dried tissues (mol/kg defatted-dried
weight) from the same individuals: the former measurements
aimed to determine whether metals in mice with hepatic steatosis
are subject to factitious lowering, and the latter to ascertain
whether any such effect can be negated by drying/defatting, and
consequently whether any actual abnormalities in the regulation of
any essential metals could be identiﬁed.
We found evidence for a marked excluded-volume effect in
untreated hepatic tissue from ob/ob livers that was resolved in
defatted-dried tissue. Thus, it proved necessary to measure copper
levels in defatted-dried tissue rather than in untreated-liver tissue,
in which major amounts of neutral lipid evidently cause spurious
lowering of metal content due to an excluded-volume effect. He-
patic Cu levels were markedly lower in defatted-dried tissue from
ob/obmice, 339 (316-361) mmol/kg defatted-dried wt (mean ± 95%
conﬁdence interval, CI) as compared to values in non-obese con-
trols, 502 (406-597); P ¼ 0.0053. These data also provide strong
evidence for speciﬁcity in that copper was the only trace metal to
show substantive lowering in the livers of ob/ob mice.
We conclude: (1) that ob/obmice develop an actual (that is, non-
factitious) and speciﬁc (with respect to other physiological metals)
hepatic copper deﬁciency state wherein levels are decreased to
~65% of normal; and (2) that these mice can serve as a suitable
model for more in-depth nonclinical studies of copper dysregula-
tion in NAFLD and NASH to determine whether this degree of
lowering of tissue copper might impair hepatic lipid regulation.
Further studies are required as a prelude to any possible future
clinical interventional studies.
2. Materials and methods
2.1. Ethics
All animal procedures were licensed by the UK Home Ofﬁce,
approved by the Institutional Animal Ethics Committee, and con-
ducted in accordance with the Animals (Scientiﬁc Procedures) Act
(1986). Study performance was consistent with the Guide for the
Care and Use of Laboratory Animals [20], and this report is
consistent with the ARRIVE guidelines for the reporting of animal
research [21].
2.2. Animal model
Male ob/obmice in the C57BL/6 background (N¼ 10) and C57BL/
6 background controls (N ¼ 7) were from Harlan Laboratories
(Hillcrest, UK) and were studied at 11e12 weeks of age. We have
previously shown that ob/ob mice at this age demonstrate marked
hepatic fat inﬁltration with clear signs of NAFLD/NASH [2,4]. Ani-
mals were maintained under a 12:12 h light:dark cycle and housed
at 22 ± 2 C and 60% humidity, with ad libitum access to standard
chow (Maintenance Rodent Diet; Special Diet Services, Essex, UK)
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known physiological requirements [22], so animals were not sub-
ject to inadequate dietary copper. On the ﬁnal experimental day,
animals were killed by cervical dislocation followed by decapita-
tion, and livers excised and stored at 80 C until analysis.
2.3. Preparation of liver extracts
Metal concentrations were determined as described here, either
on a wet-weight basis from unmodiﬁed tissue or from tissue that
had ﬁrst been dried and defatted.
For determination on a fresh-weight basis, samples of liver tis-
sue (50 ± 5 mg wet-weight) which had ﬁrst been blotted dry, were
digested as described below. For dried-defatted tissue measure-
ments, aliquots of 150 mg wet weight (±5%) were dried to constant
weight in a centrifugal concentrator (Savant Speedvac; Thermo-
Fisher, Waltham, MA).
Lipids were extracted in 2 ml 50:50 (v/v) chloroform (Acros
Organics 32667 “ECD tested for pesticide analysis”, Acros Organics,
Geel, Belgium):2,2,4-trimethylpentane (Fluka 34499 “Pestanal”
Grade, Sigma Aldrich, Gillingham, UK) using a TissueLyser II (Qia-
gen, Manchester, UK). A 3-mm Tungsten carbide bead was added to
each sample tube and samples were extracted for 10 min at 25 Hz.
Samples were vortex-mixed for 10e15 s prior to centrifugation at
2400 g for 15 min, and supernatants were removed from the
remaining tissue. Samples were then washed with 1 ml methanol
(Fluka 34966 Chromasolv LC-MS Grade, Sigma) and centrifuged at
2400 g for 15 min, supernatants removed, and samples dried
overnight. Aliquots of 10 mg (dried-delipidated weight) were
transferred into 2-ml microcentrifuge tubes (Eppendorf) for acid
digestion.
2.4. Digestion
Reactions were performed in Trace Metal Grade concentrated
nitric acid (A509 Trace Metal Grade; Fisher, Loughborough, UK) to
which had been added (5% v/v) Agilent Internal Standard mixture
(5183-4681; Agilent Technologies, Cheadle, UK). This internally-
standardised acid was also used at appropriate dilutions to pro-
vide rinse and calibration solutions, at 2% (v/v) ﬁnal nitric acid.
Calibration solutions were produced by appropriate dilutions of
Environmental Calibration Standard (Agilent 5183-4688).
Acid digestion was carried out using a simple ‘open vessel’
method. Tissue aliquots were brieﬂy centrifuged to ensure that the
tissue sat at the bottom of the tube. The tube lids were punctured to
prevent pressure build up, and 0.2 ml standard-containing nitric
acid added. Tubes were then inserted into a “Dri-block” heater
which was initially at room temperature. Tubes containing
standard-containing acid but no sample were processed in each
batch to provide “digestion” blanks. Temperature was then set to
60

C and the block switched on. After 30 min, the set temperature
was increased to 100

C, and digestion continued for a further
210 min. After digestion, the tubes were allowed to cool overnight.
100 ml aliquots of the digestion solution were then added to 15 ml
Falcon tubes (Greiner) containing 5 ml LC-MS grade water, to
produce solutions for analysis at a ﬁnal nitric acid concentration of
2% (v/v).
2.5. Metal measurements
Tissue metal concentrations were measured using an Agilent
7700x ICP-MS spectrometer with a multi-element method
including all elements present in the calibration solution. A multi-
element method was written including all components present in
the calibration solution, and following Agilent's recommendationsfor operation modes, integration times and internal standard
assignment.
For each analytical batch, multi-element calibration was per-
formed using serial dilutions of the calibration standard. An inter-
mediate concentration from this calibration series was used as a
periodic quality control (QC) sample throughout each analytical
batch. Instrument and digestion blanks were also interspersed
through each set of randomised samples. Signals derived from non-
essential elements were identiﬁed by comparison of blank, cali-
bration and sample concentrations, and eliminated prior to
reporting. We veriﬁed that the copper content of the animals’
drinking water was on average ~5.2 mg/l (i.e. >100-fold below the
maximum of 2 mg/l currently allowed in potable drinking water for
humans by current UK guidelines; http://www.dwi.gov.uk).
2.6. Statistical methods
Tabulated data are means (±95% CI). Signiﬁcance of between-
group contrasts was determined by Welch's modiﬁed t-test to
allow for unequal variances. Statistical calculations were performed
using S-plus v8.1 (Spotﬁre; TIBCO, Somerville, MA), and graphs
were plotted using GraphPad v6.04 (Prism; La Jolla, CA). P-values of
<0.05 have been considered signiﬁcant, and those of 0.05 P < 0.10
have also been tabulated.
3. Results and discussion
We ﬁrst measured the concentrations of 10 essential metals in
unmodiﬁed liver tissue from 10 ob/ob mice and seven controls by
using ICP-MS with reference isotopes for each element as shown
(Table 1). Metal concentrations were uniformly greater in control
than obese mice. The mean (±range) of ratios of metal concentra-
tions between control and obese mice was 1.4 (1.1-1.9): therefore,
ratios of concentrations between control and ob/ob mice were
~similar for all essential metals measured.
We next repeated metal measurements in liver tissue from the
same animals after samples had been dried to constant weight and
defatted (Table 2). Under these conditions, tissue copper concen-
trations were signiﬁcantly greater in control mice, 502 (406-597)
mmol/kg dried-defatted tissue, than in ob/ob mice, 339 (316-361);
the average ratio in copper concentrations between control and ob/
ob mice was 1.5 (P ¼ 0.0053). By contrast, ratios in levels of other
essential metals did not differ signiﬁcantly between the groups,
except in the case of sodiumwhere the difference was of borderline
signiﬁcance (P ¼ 0.047), and manganese, which also showed a
minor yet signiﬁcant decrease.
Plots of copper concentrations inwhole-liver tissue and in dried-
defatted liver tissue are shown in Fig. 1A, B. Copper concentrations
were increased in dried-defatted tissue by an average of 4.7-fold in
controls and 5.7-fold in ob/ob mice (Fig. 1B) compared with corre-
sponding values in whole-liver tissue (Fig. 1A). Copper concentra-
tions in dried-defatted tissue were markedly lower in ob/ob mice as
compared with matched controls (Fig. 1B), providing substantive
evidence for genuine hepatic copper deﬁciency. By contrast, the data
in Fig. 1A were confounded by an excluded-volume effect, as shown
by comparison of the data in Tables 1 and 2
Thus ob/ob mice demonstrated hepatic copper levels that were
signiﬁcantly lower than those in controls on the basis of mea-
surements in dried-defatted tissue, which are informative. This
difference was present at a time when these mice are known to
have hepatic steatosis and inﬂammation (NAFLD/NASH) [2,4].
Comparison between the pattern for copper and those for other
metals indicates that this deﬁciency is likely to occur through a
process speciﬁc for copper, as opposed to any of the other essential
metals. The exact molecular mechanism by which copper becomes
Table 1
Metal concentrations of unmodiﬁed liver tissue from ob/ob mice and non-obese controls.
Metal Reference isotope Control (N ¼ 7) ob/ob (N ¼ 10) P-value*
Na (mmol/kg wet wt) 23Na 29.1(27.1-31.2) 22.0 (20.6-23.4) <0.0001
Mg(mmol/kg wet wt 24Mg 11.3(9.9-12.7) 8.6(7.8-9.4) 0.0022
K(mmol/kg wet wt) 39K 97.4(90.4-104.3) 76.0(69.5-82.4) 0.0001
Ca(mmol/kg wet wt) 44Ca 754(672-835) 580(497-662) 0.003
Mn(mmol/kg wet wt) 55Mn 25.2(21.5-28.9) 13.2(11.8-14.6) 0.0001
Fe(mmol/kg wet wt) 56Fe 1055(891-1292) 730(624-836) 0.015
Cu(mmol/kg wet wt) 63Cu 106(93-119) 59(52.5-62.5) <0.0001
Zn(mmol/kg wet wt) 66Zn 467(416-518) 379(337-421) 0.007
Se(mmol/kg wet wt) 78Se 20.8(17.9-23.8) 13.6(11.7-15.4) 0.0004
Mo(mmol/kg wet wt) 95Mo 10.8(9.5-12.2) 9.5(8.5-10.4) 0.067
Data are means (±95% CI).
*Signiﬁcance of between-group differences by Welch's modiﬁed t-tests.
Table 2
Metal concentrations in defatted-dried liver tissue from ob/ob mice and non-obese controls.
Metal Reference isotope control(N ¼ 7) ob/ob(N ¼ 10) P-value*
Na(mmol/kg defatted-dried wt) 23Na 28.3(18.8-37.8) 18.3(15.0-20.8) 0.047
Mg(mmol/kg defatted-dried wt) 24Mg 38.4(26.0-50.7) 35.4(32.6-38.3) NS
K(mmol/kg defatted-dried wt) 39K 134(97-171) 104(91-117) NS
Ca(mmol/kg defatted-dried wt) 44Ca 3.4(2.7-4.2) 3.0(2.8-3.3) NS
Mn(mmol/kg defatted-dried wt) 55Mn 102(72-133) 68.9(63.9-74.0) 0.037
Fe(mmol/kg defatted-dried wt) 56Fe 4.3(3.3-5.4) 3.5(3.0-4.0) NS
Cu(mmol/kg defatted-dried wt) 63Cu 502(406-597) 339(316-361) 0.0053
Zn(mmol/kg defatted dry wt) 66Zn 1.9(1.6-2.1) 1.9(1.8-2.1) NS
Se(mmol/kg defatted dry wt) 78Se 75.9(63.6-88.5) 63.7(58.8-68.6) 0.059
Mo(mmol/kg defatted-dried wt) 95Mo 42.0(35.1-48.9) 47.6(45.0-50.3) NS
Data are means (±95% CI).
*Signiﬁcance of between-group differences by Welch's modiﬁed t-test.
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could mirror that which causes myocardial copper deﬁciency and
cardiac damage in diabetic cardiomyopathy, where there is sub-
stantive evidence that diabetes can evoke regulatory defects in
many of the pathways that mediate myocellular copper uptake and
distribution [13].
Here, hepatic copper deﬁciency in ob/obmice was unmasked by
measuring metal levels in defatted-dried tissue (Table 2): this
obviated the interference that was caused by the excluded-volume
effect of elevated hepatocellular lipids (HCL) when metal levels
were measured in unmodiﬁed hepatic tissue (Table 1). These
ﬁndings show that subsequent studies of dysregulated copper
metabolism in the livers of ob/obmice, and related obese or diabetic
states in animals and patients with hepatic steatosis, will need to be
undertaken using dry-defatted liver tissue.Fig. 1. Copper concentrations in hepatic tissue from ob/ob (N ¼ 10) and C57BL/6 contol (N
centrations in hepatic tissue that had been dried to constant weight and defatted prior to an
thin horizontal lines indicate mean values, and short-thick lines ± standard deviation.Copper deﬁciency can cause neurodegeneration as well as car-
diovascular and haematological disorders (reviewed in Ref. [23])
via impairment of cellular antioxidant defences and concomitant
defects in copper-mediated processes and pathways [13]: these
effects are thought to cause formation of excessive amounts of
reactive oxygen species (ROS) in affected tissues. Identiﬁed path-
ogenic mechanisms include defective superoxide clearance caused
by impaired copper metalation and activity of superoxide dismut-
ase 1 (SOD1) [13], a copper/zinc enzyme; and defective activity of
cytochrome c oxidase subunits CO1 and CO2 - both of which are
copper enzymes (reviewed in Ref. [24]).
Hepatic steatosis is deﬁned by an increased content of HCL and
is frequently observed in the context of insulin resistance, for
example in obesity and type-2 diabetes. Elevations in HCL are
generally thought to result from dietary excess of saturated fat¼ 6) mice. (A) Copper concentrations in unmodiﬁed hepatic tissue. (B) Copper con-
alysis. Copper was measured by inductively-coupled plasma mass spectrometry. Long-
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ance [25]. However, hepatic steatosis is also well known to occur as
a result of toxic injury to the liver, for example that caused by
exposure to halogenated hydrocarbons such as carbon tetrachlo-
ride: such processes can also cause marked elevations in HCL
through the formation of free radicals that damage hepatocytes,
thus preventing them from synthesising lipoprotein from tri-
glycerides [26]. Therefore, it is possible that copper deﬁciency could
contribute to or cause liver injury via enhanced tissue ROS forma-
tion rather than simple ‘spill-over’ of excess dietary lipid.
Our data are consistent with the idea that the lowered levels of
hepatic copper measured here in ob/ob mice could be sufﬁcient to
contribute to the hepatic steatosis and inﬂammation that occur in
these mice. Hepatic steatosis has been linked to low liver copper
levels in animals receiving low-copper diets [27,28]. Thus, it is
possible that hepatic copper deﬁciency could be a contributory
cause rather than a consequence of hepatic steatosis in obesity and
diabetes: this state may not be caused solely by elevated dietary
lipid intake or defective hepatic lipid clearance. Rather, it may
represent a manifestation of liver injury caused by hepatic copper
deﬁciency leading to organ pathology via mechanisms similar to
those by which diabetes causes myocardial copper deﬁciency and
cardiomyopathy [13].
In summary, we report here that ob/ob mice develop substan-
tively deﬁcient hepatic copper levels at an age at which they
manifest signs of metabolic liver disease. This localised copper-
deﬁciency state appears to be speciﬁc for copper as opposed to
other essential metals and occurs in animals that do not display
signs of systemic copper homeostasis. Therefore, the hepatic cop-
per deﬁciency in ob/ob mice reﬂects a localised process. The mo-
lecular mechanisms responsible for hepatic copper deﬁciency in ob/
obmice could reﬂect those that cause myocardial copper deﬁciency
and tissue damage in diabetic cardiomyopathy. Whether low he-
patic copper levels occur in patients with NAFLD or NASH, and
could contribute to the pathogenesis of these diseases in animals or
patients, remains to be determined.
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